human
rhinovirus
hrv
major
caus
upper
respiratori
tract
symptom
common
cold
human
name
reflect
primari
site
infect
hrv
nonenvelop
icosahedr
virus
small
size
diamet
nm
pico
small
latin
consist
rna
genom
assign
famili
picornavirida
current
viru
famili
order
picornaviral
compris
eight
genera
enteroviru
hepatoviru
cardioviru
kobuviru
teschoviru
erboviru
aphthoviru
parechoviru
speci
multitud
high
similar
genom
sequenc
genom
organ
fig
former
genera
rhinoviru
enteroviru
combin
recent
keep
exist
name
enteroviru
http
wwwpicornastudygroupcomtaxaspeciesspecieshtm
overview
current
taxonomi
picornavirus
pathogen
human
well
newli
propos
speci
hrv
given
tabl
present
genu
enteroviru
includ
four
approv
human
enteroviru
hev
speci
two
approv
hrv
speci
http
wwwpicornastudygroupcomtaxaspeciesspecieshtm
sinc
global
distribut
highli
diverg
hrv
strain
base
result
sequenc
genom
phylogenet
analys
propos
strain
repres
new
hrv
speci
propos
concern
new
potenti
speci
publish
sequenc
analysi
known
hrv
approv
newli
propos
speci
genu
enteroviru
share
homolog
averag
amino
acid
ident
precapsid
protein
well
differ
antigen
properti
provid
basi
divis
speci
serotyp
tabl
rhinoviru
serotyp
current
known
accord
current
approv
taxonomi
hrv
hank
belong
genom
known
serotyp
well
sever
field
isol
sequenc
virus
classifi
could
grown
cell
cultur
phylogenet
analys
perform
partial
well
whole
recent
comprehens
analysi
known
hrv
genom
reveal
share
common
ancestor
sister
group
ii
repres
third
speci
iii
basal
diverg
within
three
distinct
strain
led
propos
fourth
speci
often
induc
mild
usual
upper
respiratori
ill
human
character
nasal
stuffi
discharg
sneez
sore
throat
cough
convent
term
common
cold
common
cold
heterogen
group
diseas
caus
numer
virus
belong
sever
differ
famili
eg
rhinovirus
coronavirus
enterovirus
hrv
repres
common
etiolog
agent
worldwid
larg
number
distinct
strain
circul
moreov
famili
even
singl
specimen
multipl
hrv
serotyp
detect
use
cultur
shown
hrv
induc
upper
respiratori
tract
infect
adult
well
higher
incid
describ
septemb
april
year
perhap
geograph
area
spring
import
time
rhinoviru
although
overal
rate
respiratori
ill
lower
summer
rhinovirus
frequent
isol
time
incid
invers
proport
age
year
children
antibodi
addit
common
cold
hrv
also
involv
acut
otiti
media
moreov
data
support
caus
associ
sever
lower
respiratori
tract
infect
infant
elderli
person
immunocompromis
patient
studi
childhood
adult
asthma
shown
hrv
infect
also
trigger
exacerb
patient
chronic
obstruct
pulmonari
cystic
recent
discov
novel
rhinoviru
genotyp
associ
commun
outbreak
acut
upper
respiratori
infect
sever
low
respiratori
tract
infect
infant
eg
febril
wheez
bronchiolyti
asthma
exacerb
peak
fall
addit
presenc
middl
ear
patient
acut
otiti
media
hrv
spread
occur
mean
respiratori
secret
contain
high
viru
besid
direct
transmiss
aerosol
transmiss
rhinovirus
children
import
vector
hrv
transmiss
famili
moreov
studi
natur
adult
provid
evid
daili
activ
infect
peopl
lead
contamin
environment
surfac
hrv
eg
light
switch
telephon
dial
button
handset
viru
transfer
finger
healthi
individu
viral
contamin
hand
play
import
role
transmiss
hrv
interrupt
step
viru
transmiss
present
potenti
target
intervent
experiment
prove
treatment
hand
salicyl
pyroglutam
observ
experiment
induc
infect
normal
adult
volunt
help
understand
pathogenesi
hrv
human
infecti
dose
rhinoviru
low
infect
rate
deposit
hrv
nasal
conjunctiv
mucosa
virus
transport
posterior
nasopharynx
mucociliari
action
epitheli
cell
specif
receptor
epitheli
cell
adenoid
area
use
bind
entri
alreadi
hr
intranas
inocul
infecti
viru
viru
shed
peak
second
day
infect
decreas
rapidli
small
amount
virus
discov
nasal
secret
week
infect
viru
andor
viral
rna
demonstr
well
lower
respiratori
use
situ
hybrid
arruda
et
al
detect
viral
rna
low
number
ciliat
cell
nasal
biopsi
nasopharynx
small
portion
ciliat
well
noncili
cell
posit
viral
rna
papadopoulo
et
al
provid
evid
hrv
may
also
lytic
infect
human
bronchial
epitheli
cell
cell
cultur
well
experiment
infect
volunt
induc
product
agreement
result
hrv
rna
detect
children
adult
taken
togeth
result
natur
cold
studi
well
experiment
infect
human
volunt
clearli
demonstr
hrv
abl
replic
upper
well
lower
airway
hrv
infect
trigger
vasodil
increas
vascular
permeabl
nasal
mucosa
lead
nasal
obstruct
rhinorrhoea
mechan
still
incomplet
understood
histopatholog
chang
observ
nasal
biopsi
specimen
infect
led
suggest
clinic
symptom
primarili
caus
inflammatori
respons
host
viru
infect
cytopath
effect
cpe
hrv
result
immunolog
investig
suggest
modest
correl
concentr
nasal
secret
sever
symptom
upper
lower
respiratori
tract
day
viru
challeng
concentr
significantli
greater
nasal
secret
experiment
infect
symptomat
subject
infect
asymptomat
subject
propos
mediat
neutrophil
infiltr
observ
symptomat
infect
experiment
rhinoviru
infect
onset
symptom
eg
nasal
stuffi
discharg
sneez
cough
observ
hr
intranas
inocul
contrast
rhinoviru
infect
adult
fever
found
children
upper
respiratori
tract
symptom
children
adult
may
hoars
headach
malais
lethargi
sometim
viral
infect
accompani
bacteri
complic
lead
instanc
acut
otiti
media
infect
children
sinus
experiment
infect
also
use
studi
causat
rhinoviru
infect
asthma
well
copd
shown
hrv
infect
enhanc
airway
reactiv
predispos
allerg
patient
develop
late
asthmat
rhinovir
cold
associ
increas
histamin
respons
accompani
bronchial
mucos
lymphocyt
eosinophil
recent
studi
increas
clinic
ill
sever
asthmat
compar
normal
subject
strong
relationship
shown
viru
load
lower
airway
inflamm
asthma
exacerb
sever
result
studi
also
indic
augment
impair
immun
like
import
mechan
mallia
et
al
provid
evid
low
dose
experiment
rhinoviru
infect
patient
copd
induc
symptom
lung
function
chang
typic
acut
exacerb
viral
replic
increas
cytokin
respons
associ
symptomat
cold
increas
lower
respiratori
tract
symptom
reduct
forc
expiratori
volum
peak
expiratori
flow
rate
epidemiolog
data
patholog
hrv
infect
explain
high
medic
impact
million
children
adult
taken
ill
common
cold
everi
year
need
medic
consult
unabl
attend
school
go
direct
cost
includ
hospit
medic
fee
symptomat
treatment
moreov
exacerb
major
caus
asthma
copd
morbid
mortal
health
care
cost
associ
date
specif
drug
prevent
reduc
rhinoviru
infect
avail
common
cold
treat
symptomat
analges
decongest
antihistamin
antituss
antibiot
often
wrongli
larg
number
circul
hrv
serotyp
treatment
specif
antivir
drug
consid
strike
vaccin
therefor
search
new
highli
activ
synthet
andor
natur
compound
absolut
essenti
repres
import
area
antivir
research
drug
would
broad
spectrum
activ
high
number
hrv
serotyp
ii
administ
earli
infect
demonstr
good
antivir
effect
fast
infect
kinet
iii
safe
broad
applic
million
peopl
iv
direct
highli
conserv
target
low
risk
resist
develop
due
high
error
rate
lack
proofread
abil
rna
polymeras
natur
variant
may
exist
viru
popul
resist
virus
emerg
treatment
hiv
anoth
highli
variabl
rna
viru
risk
resist
develop
andor
select
resist
viru
variant
could
minim
appli
combin
drug
direct
differ
target
clinic
symptom
suggest
primarili
caus
inflammatori
respons
host
viru
infect
mediat
specif
cytokin
advantag
drug
combin
could
addit
activ
hrv
grow
sever
human
primat
cell
express
minor
group
ldl
receptor
andor
major
group
receptor
human
cell
suscept
hrv
infect
includ
embryon
kidney
amnion
diploid
fibroblast
embryon
lung
tonsil
liver
intestin
skin
adult
fibroblast
line
aorta
gingiv
kb
hela
continu
cell
suscept
hela
cell
human
fibroblast
viru
infect
may
hrv
multipl
also
occur
primari
human
airway
differenti
bronchial
proport
infect
epitheli
cell
shown
enhanc
level
viral
product
detect
poorli
differenti
comparison
differenti
epitheli
degre
viral
infect
correl
induct
cell
viru
growth
caus
typic
cpe
character
balloon
refract
granular
shrinkag
infect
cell
cpe
infecti
viru
titer
viral
protein
express
rna
synthesi
chosen
paramet
evalu
activ
compound
base
assay
sever
method
antivir
screen
hrv
plaqu
reduct
assay
tradit
perform
accept
gold
standard
antivir
howev
test
labori
time
consum
evalu
subject
therefor
suit
routin
antivir
test
replac
method
base
quantif
protect
cpe
drug
treatment
cpe
untreat
cell
compar
light
evalu
also
subject
anoth
object
approach
spectrophotometr
quantif
cpe
result
neutral
red
crystal
violet
uptak
tetrazolium
dye
reduct
allow
excel
rapid
antivir
screen
larg
number
compound
use
small
amount
extract
natur
synthet
compound
activ
sampl
schedul
addit
test
use
assay
eg
viru
yield
plaqu
reduct
assay
studi
mechan
action
activ
potenti
antivir
drug
approv
vivo
high
degre
variat
prevent
infect
major
group
hrv
practic
anim
model
absent
long
time
chimpanze
infect
sever
hrv
serotyp
without
develop
clinic
hrv
induc
infect
rabbit
guinea
pig
weanl
mice
inject
hrv
differ
rout
one
minor
group
hrv
serotyp
adapt
grow
mous
fibroblast
use
mous
model
rhinoviru
infect
growth
could
base
fact
ldl
receptor
famili
highli
conserv
human
mous
newcomb
et
al
examin
whether
anoth
minor
group
viru
may
infect
mous
airway
femal
author
demonstr
hrv
serotyp
replic
induc
airway
inflamm
vivo
result
strongli
correspond
bartlett
et
al
establish
three
novel
mous
model
rhinoviru
infect
first
model
balbc
mice
infect
second
model
transgen
balbc
mice
express
chimera
inocul
major
group
exacerb
allerg
airway
inflamm
mimick
third
model
due
lack
model
hrv
infect
experiment
human
challeng
model
use
approv
effect
potenti
antivir
drug
control
condit
preclin
studi
volunt
experiment
inocul
variou
serotyp
eg
examin
efficaci
potenti
antivir
drug
standard
exampl
result
studi
proteas
rna
synthesi
inhibitor
well
interferon
describ
follow
section
inhibit
viru
attach
andor
uncoat
interrupt
viral
life
cycl
begin
prevent
hrv
infect
option
prevent
earli
step
viral
life
cycl
includ
viru
neutral
antibodi
ii
receptor
blockad
antibodi
direct
cellular
receptor
ldl
iii
solubl
receptor
molecul
iv
compound
interact
viral
capsid
high
number
serotyp
circul
often
parallel
applic
antibodi
thought
promis
approach
prevent
therapi
rhinoviru
infect
contrast
antibodi
direct
cellular
receptor
solubl
receptor
molecul
major
minor
group
hrv
could
inhibit
hrv
serotyp
respect
therefor
strategi
prevent
interact
receptor
antibodi
solubl
receptor
molecul
extens
evalu
vitro
well
vivo
antivir
activ
antibodi
confirm
cell
furthermor
prophylact
effect
safeti
intranas
administ
rhinoviru
murin
antibodi
assess
two
random
studi
volunt
experiment
inocul
result
toxic
relat
antibodi
applic
recogn
higher
dosag
mgsubject
rhinoviru
murin
receptor
antibodi
reduc
overal
infect
ill
rate
associ
day
delay
onset
viru
shed
cold
symptom
viral
titer
nasal
symptom
significantli
reduc
second
day
challeng
summari
monoclon
antibodi
cellular
demonstr
effect
enough
new
strategi
creation
multival
fab
fusion
protein
new
molecul
name
demonstr
better
avid
vitro
potenc
hrv
convent
develop
nasal
spray
name
coldsol
antagon
interact
consid
anoth
promis
way
prevent
hrv
attach
host
cell
solubl
form
fulli
truncat
ldl
exhibit
antivir
activ
major
minor
group
hrv
respect
cell
cultur
solubl
form
compet
receptor
bind
site
viru
capsid
hinder
earli
infect
event
entri
uncoat
directli
inactiv
hrv
due
format
empti
solubl
ldl
receptor
fragment
neutral
viral
infect
concatem
third
ligand
bind
modul
lead
viral
aggreg
block
receptor
bind
site
possibl
inhibit
viral
uncoat
viral
capsid
subunit
via
antivir
activ
truncat
solubl
form
prove
infect
random
trial
safeti
efficaci
intranas
administr
tremacamra
solubl
experiment
cold
human
develop
report
option
prevent
viru
attach
describ
compound
agent
enter
small
hydrophob
pocket
within
viral
capsid
protein
beneath
canyon
zhang
et
al
show
drug
may
integr
matur
virus
diffus
well
progeni
virus
grown
presenc
pleconaril
higher
occup
occur
drug
introduc
virus
induc
conform
chang
canyon
hinder
interact
prevent
attach
host
addit
uncoat
hrv
serotyp
shown
inhibit
result
potenti
loss
flexibl
viral
capsid
drug
bind
contrast
compound
prevent
attach
result
studi
show
drug
bind
hydrophob
pocket
replac
pocket
factor
induc
small
conform
therefor
kim
et
al
suggest
observ
conform
chang
small
affect
receptor
bind
compound
prevent
attach
possess
pocket
factor
like
without
distinct
deform
result
compar
antivir
studi
differ
compound
hrv
repres
major
minor
group
reveal
correl
inhibit
adsorpt
receptor
group
antivir
reason
differ
mode
action
compound
relat
attach
inhibit
fulli
understood
taken
togeth
inhibit
rna
uncoat
found
investig
serotyp
drug
bind
independ
receptor
group
wherea
prevent
viru
attach
found
addit
mode
action
individu
virus
andor
drug
till
variou
potent
compound
belong
divers
chemic
class
describ
uncoat
inhibitor
give
impress
divers
structur
disoxaril
pirodavir
oxim
isoxazol
deriv
imidazol
deriv
sch
chalcon
ro
dichloroflavan
pyridin
deriv
mdl
phenoxybenzen
exhibit
potent
activ
tabl
ii
shown
exampl
figur
inhibit
hrv
serotyp
coupl
also
affect
enterovirus
howev
vari
suscept
base
variabl
suscept
differ
length
hrv
serotyp
classifi
two
differ
group
sever
given
exampl
compound
also
clinic
test
studi
develop
clinic
effect
long
road
discoveri
clinic
effect
drug
becom
appar
one
exampl
repres
discoveri
optim
sterl
winthrop
pharmaceut
group
win
first
inhibitor
origin
juvenil
hormon
mimet
demonstr
activ
determin
structur
help
understand
compound
bind
site
viru
result
subsequ
studi
compound
complex
reveal
locat
natur
bind
site
provid
inform
concern
interact
within
knowledg
use
optim
design
new
optim
win
compound
exampl
disoxaril
pleconaril
fig
consist
methylisoxazol
ring
substitut
phenoxi
group
heteroatom
ring
inhibit
broad
spectrum
rhinovirus
enterovirus
tabl
ii
first
win
compound
disoxaril
win
test
clinic
develop
crystallurea
human
volunt
treat
high
dose
well
low
bioavail
prohibit
subsequ
develop
thereaft
result
sar
qsar
analysi
use
enhanc
potenc
spectrum
activ
anoth
compound
win
clinic
test
effect
human
infect
moreov
rapidli
metabol
induc
revers
hepat
consequ
clinic
develop
stop
better
understand
pharmacokinet
properti
capsid
binder
synthet
chemistri
effort
led
discoveri
pleconaril
oral
bioavail
inhibit
rhinoviru
well
variou
enteroviru
schiff
et
al
publish
efficaci
pleconaril
experiment
induc
coxsackieviru
infect
phase
ii
natur
cold
trial
drug
produc
moder
reduct
day
medium
time
elev
ill
compar
result
confirm
two
subsequ
pivot
besid
moder
clinic
efficaci
studi
reveal
baselin
isol
suscept
pleconaril
develop
reduc
suscept
defin
increas
baselin
valu
subsequ
studi
relationship
pleconaril
suscept
clinic
outcom
treatment
common
cold
caus
rhinovirus
base
drug
interact
margin
treatment
effect
possibl
transmiss
resist
virus
fda
approv
appli
oral
administr
pleconaril
treatment
common
cold
molecular
mechan
drug
interact
oral
given
pleconaril
shown
base
hepat
cytochrom
reduc
advers
effect
licens
viropharma
complet
phase
ii
clinic
trial
intranas
formul
pleconaril
potenti
treatment
common
cold
popul
result
publish
pyridazin
analogu
develop
janssen
research
foundat
repres
anoth
exampl
long
road
discoveri
clinic
effect
activ
pirodavir
fig
tabl
ii
rhinovirus
year
result
random
trail
assess
therapeut
efficaci
intranas
pirodavir
natur
common
cold
possibl
result
poor
water
solubl
rapid
hydrolysi
pirodavir
clinic
benefit
found
problem
ester
hydrolysi
resolv
develop
oxim
ether
analogu
pirodavir
biota
exampl
shown
figur
like
pirodavir
new
analogu
potent
inhibitor
advantag
pirodavir
improv
bioavail
antivir
analogu
long
good
oral
bioavail
schedul
phase
ii
clinic
trial
result
yet
publish
summari
despit
extens
research
lead
discoveri
potent
agent
approv
prevent
andor
therapi
diseas
far
nearli
conclus
drawn
proteas
inhibitor
pivot
role
viral
polyprotein
process
high
conserv
critic
amino
well
repres
potenti
target
result
cell
assay
provid
evid
inhibit
hrv
replic
principl
possibl
exampl
process
polyprotein
prevent
pyrrolidin
dithiocarbam
treatment
hela
contrast
pretreat
cell
monolay
differ
nitric
oxid
donor
lead
neither
effect
viru
replic
proteolyt
activ
specif
inhibit
two
antivir
peptid
repres
deriv
caspas
inhibitor
homophthalimid
eg
fig
tabl
ii
describ
inhibitor
well
contrast
proteas
relationship
studi
report
hrv
proteas
moreov
proteas
accomplish
one
cleavag
hrv
polyprotein
proteas
perform
cleavag
elucid
crystal
structur
comput
model
structur
featur
proteas
inhibitor
becam
furthermor
design
use
develop
inhibitor
proteas
potent
antivir
activ
multipl
hrv
highli
activ
compound
incorpor
variou
michael
acceptor
moieti
irrevers
bind
exhibit
activ
hela
studi
perform
optim
proteas
effort
result
identif
highli
activ
compound
rupintrivir
fig
tabl
ii
enter
clinic
trial
cell
cultur
inhibit
broad
spectrum
laboratori
hrv
well
clinic
assay
demonstr
antivir
activ
ad
hr
inhibit
hrv
replic
strongli
correl
reduct
level
releas
cell
supernat
lead
suggest
agent
may
block
viru
replic
also
diminish
pharmacokinet
safeti
rupintrivir
prove
two
random
intranas
rupintrivir
administ
singl
dose
mg
everi
hr
six
time
per
day
day
safe
well
toler
three
doubl
blind
clinic
trial
conduct
assess
rupintrivir
nasal
spray
solut
prevent
treatment
experiment
induc
rhinoviru
cold
healthi
rupintrivir
prophylaxi
reduc
proport
subject
posit
viral
cultur
viral
titer
decreas
frequenc
cold
drug
treatment
led
reduct
mean
total
daili
symptom
score
subject
receiv
rupintrivir
also
demonstr
significantli
lower
viral
titer
rna
level
subject
day
day
respect
influenc
proport
subject
posit
viral
cultur
frequenc
cold
clinic
develop
termin
rupintrivir
act
subsequ
natur
infect
studi
parallel
research
effort
oral
bioavail
inhibitor
hrv
ie
e
acid
ethyl
ester
fig
tabl
ii
like
rupintrivir
compound
irrevers
inhibitor
incorpor
michael
acceptor
moieti
form
coval
bond
proteas
activ
site
cystein
demonstr
antivir
activ
hrv
relat
picornavirus
phase
clinic
studi
compound
shown
safe
well
toler
accord
public
patick
clinic
develop
plan
block
viral
rna
synthesi
replic
repres
anoth
site
chemotherapeut
interdict
shown
rhinovir
rna
target
manner
morpholino
small
interf
ribonucl
efficaci
latter
two
approach
confirm
cell
cultur
addit
chlorid
fig
tabl
ii
flavonoid
exampl
fig
tabl
iii
pyrrolidin
dithiocarbam
fig
interf
rhinovir
rna
synthesi
inhibit
hrv
replic
cell
nucleosid
analog
ribavirin
fig
tabl
ii
inhibit
broad
spectrum
rna
well
dna
virus
act
also
hela
cellular
inosin
monophosph
dehydrogenas
control
de
novo
synthesi
purin
nucleosid
repres
princip
target
mode
action
moreov
ribavirin
incorpor
picornaviru
rna
pair
equal
well
either
uracil
cytosin
induc
mutat
lethal
rna
identifi
mechan
action
ribavirin
includ
inhibit
genom
rna
cap
enhanc
host
immun
viral
infect
help
switch
host
phenotyp
type
type
anoth
compound
potent
activ
vitro
enviroxim
fig
tabl
ii
benzimidazol
inhibit
viral
plu
strand
rna
particular
protein
involv
initi
plu
strand
rna
synthesi
implic
like
target
drug
howev
result
anoth
studi
suggest
enviroxim
target
complex
protein
andor
cellular
factor
exact
mechan
remain
although
statist
signific
reduct
clinic
score
prophylact
studi
enviroxim
fail
experiment
induc
clinic
poor
bioavail
side
effect
attempt
overcom
mark
hydrophob
water
insolubl
toxic
wyde
et
al
incorpor
enviroxim
liposom
test
activ
toxic
enviroxim
cell
liposom
prepar
enviroxim
inhibit
effect
parent
compound
less
toxic
contrast
free
enviroxim
liposom
prepar
readili
success
deliv
aerosol
upper
lower
respiratori
tract
mice
anoth
attempt
overcom
disadvantag
enviroxim
sever
benzimidazol
well
nonbenzimidazol
analog
synthes
even
though
compound
better
bioavail
could
administ
none
compound
test
clinic
studi
besid
target
cellular
inhibitor
like
interferon
may
repres
therapeut
approach
among
activ
interferon
exhibit
antivir
activ
advantag
interferon
applic
includ
broad
spectrum
activ
low
risk
resist
develop
human
leukocyt
fibroblast
well
recombin
human
interferon
prevent
cpe
cell
cultur
wherea
variat
sensit
intranas
appli
recombin
interferon
interferon
shown
effect
human
provid
prophylact
experiment
natur
rhinoviru
signific
reduct
ill
frequenc
mean
symptom
score
nasal
secret
weight
frequenc
viru
isol
observ
contrast
recombin
interferon
prevent
hrv
infect
ill
may
enhanc
littl
therapeut
effect
found
patient
common
cold
interferon
moreov
mucu
nasal
bleed
describ
side
combin
interferon
dichloroflavan
enviroxim
chalcon
produc
synergist
increas
antivir
activ
vitro
attempt
demonstr
synergi
effect
recombin
human
rhuifn
enviroxim
volunt
accord
author
main
reason
failur
may
rapid
remov
enviroxim
nose
given
intranas
natur
provid
astonish
pool
secondari
metabolit
biosynthes
live
organ
plant
fungi
protozoan
insect
anim
sourc
contrast
synthet
compound
natur
product
character
overwhelm
chemic
divers
previous
chemic
divers
space
two
group
evalu
respect
drug
substanc
feher
shown
combinatori
compound
dens
popul
small
area
wherea
natur
product
cover
wider
rang
quit
similar
chemic
space
occupi
drug
substanc
author
accordingli
suggest
combinatori
librari
mimic
distribut
properti
natur
product
might
biolog
relev
one
may
assum
secondari
metabolit
evolv
reaction
target
receptor
relat
defenc
protect
attract
signal
adapt
process
enrich
metabolit
structur
divers
also
optim
metabol
trait
like
favor
pharmacokinet
evolutionari
concept
give
pool
natur
product
greatest
sourc
scaffold
divers
molecul
biolog
relev
newman
cragg
analyz
number
drug
approv
circumstanti
especi
area
strongli
depend
natur
product
structur
deriv
natur
includ
antivir
vaccin
launch
drug
far
major
categori
synthet
origin
vaccin
antivir
drug
approv
exclud
high
number
vaccin
biolog
small
antivir
molecul
base
nucleosid
structur
peptidomimet
classifi
total
synthet
drug
howev
till
neither
synthet
natur
deriv
drug
substanc
approv
treatment
prevent
hrv
infect
intens
research
develop
effort
field
natur
product
reveal
sever
inhibitor
viral
attach
entri
inhibitor
viral
proteas
natur
sourc
efficaci
natur
product
reflect
statist
launch
drug
also
empir
knowledg
gain
centuri
success
applic
ethnomedicin
product
plant
culinari
herb
spice
phytochem
pharmacolog
work
perform
ethnomedicin
mainli
plant
reveal
high
number
activ
metabolit
differ
chemic
class
eg
coumarin
flavonoid
alkaloid
quinon
terpenoid
polyphenol
polysaccharid
natur
product
includ
complex
extract
chemic
entiti
biosynthes
natur
unambigu
present
natur
product
prior
import
first
distinguish
singl
chemic
entiti
natur
ie
isol
purifi
natur
compound
one
hand
natur
prepar
compris
hundr
thousand
constitu
mainli
secondari
metabolit
hand
natur
prepar
deriv
plant
might
also
label
botan
phytoceut
phytotherapeut
agent
multicompon
prepar
might
show
vari
profil
constitu
depend
use
speci
origin
collect
time
plant
part
extract
procedur
prepar
method
manufactur
process
mention
import
element
paramet
affect
final
product
term
qualit
quantit
composit
chemic
constitu
may
impact
biolog
activ
accordingli
studi
perform
phytochem
specifi
extract
nonstandard
prepar
often
suffer
irreproduc
incompar
result
echinacea
prepar
includ
express
juic
aerial
part
well
extract
root
aerial
part
one
speci
genu
echinacea
e
angustifolia
e
purpurea
e
pallida
recogn
botan
prevent
treatment
common
cold
flu
account
second
herbal
product
accordingli
echinacea
come
much
scientif
scrutini
high
number
studi
deal
effect
echinacea
prevent
treat
common
cold
clinic
trial
recent
review
woelkart
et
author
summar
find
regard
random
control
trial
evalu
cochran
random
clinic
trial
analyz
shah
et
experiment
studi
pool
schoop
et
sum
clinic
data
echinacea
far
fulli
consist
mainli
base
problem
inher
assess
efficaci
echinacea
prepar
lack
compar
avail
prepar
studi
design
outcom
nevertheless
show
evid
prepar
base
aerial
part
echinacea
purpurea
might
effect
earli
treatment
cold
echinacea
show
decreas
odd
develop
common
cold
durat
cold
similarli
evalu
three
induc
rhinoviru
prevent
studi
reveal
odd
experienc
clinic
cold
higher
placebo
step
molecular
level
sever
constitu
found
echinacea
speci
could
potenti
affect
symptom
common
cold
chemic
identifi
substanc
includ
polysaccharid
glycoprotein
caffeic
acid
deriv
especi
cichor
acid
echinacosid
lipophil
polyacetylen
alkamid
pharmacolog
studi
shown
cichor
acid
alkamid
glycoprotein
polysaccharid
possess
immunomodulatori
activ
addit
alkamid
report
exert
effect
also
cannabinomimet
properti
suggest
molecular
mode
action
echinacea
alkamid
immunomodulatori
radun
et
al
show
echinacea
alkamid
exert
cannabinoid
type
independ
immunomodulatori
effect
cytokin
differ
echinacea
constitu
evalu
effect
measur
inhibit
vitro
cu
ii
oxid
human
lipoprotein
therebi
major
caffeic
acid
deriv
cichor
acid
echinacosid
show
highest
effect
even
higher
combin
natur
mixtur
sharma
et
al
use
cytokin
antibodi
array
investig
chang
cytokin
chemokin
releas
human
bronchial
epitheli
cell
expos
hrv
applic
two
chemic
character
echinacea
extract
show
revers
stimul
releas
numer
molecul
eg
cytokin
chemokin
eotaxin
similar
studi
echinacea
extract
rich
polysaccharid
anoth
rich
alkamid
caffeic
acid
deriv
well
abl
neutral
effect
epitheli
use
gene
express
analysi
studi
reveal
benefit
echinacea
prepar
involv
multipl
immun
respons
signal
pathway
taken
togeth
numer
pharmacolog
find
literatur
potenti
echinacea
prepar
constitu
combat
prevent
common
cold
deduc
immun
modul
properti
may
also
act
combin
event
rather
act
directli
hrv
garlic
clove
use
tradit
treat
number
infecti
diseas
howev
confirmatori
studi
publish
regard
tradit
antivir
use
clinic
effect
garlic
prevent
common
cold
investig
josl
publish
placebo
control
studi
assess
patient
treatment
period
garlic
common
cold
infect
symptom
record
daili
diari
patient
treatment
group
significantli
fewer
cold
patient
placebo
group
vs
p
also
longer
durat
symptom
vs
day
p
soon
garlic
chew
cut
press
main
ingredi
sulphur
contain
alliin
broken
enzym
alliinas
thiosulfin
allicin
steam
distil
allicin
transform
diallyl
disulfid
diallyl
trisulfid
respons
distinct
smell
garlic
allicin
transform
compound
found
fresh
garlic
lipophil
extract
investig
differ
garlic
extract
isol
number
differ
human
patholog
virus
weber
et
al
could
show
allicin
activ
virucid
compon
fresh
garlic
fresh
result
direct
incub
assay
let
suggest
allicin
bind
viral
protein
capsid
lead
subsequ
inhibit
viral
adsorpt
penetr
although
garlic
thiosulfin
endow
signific
cytotox
antivir
effect
obtain
nontox
besid
direct
effect
fresh
garlic
extract
allicin
number
human
immun
function
found
enhanc
vitro
aqueou
garlic
extract
polar
thiosulfin
north
america
panax
quinquefolium
ginseng
speci
indigen
canada
unit
state
popular
herbal
remedi
combat
stress
modul
natur
acquir
immun
respons
american
ginseng
root
extract
rich
found
efficaci
prevent
upper
respiratori
infect
immunocompet
healthi
random
placebo
control
trial
mg
proprietari
american
ginseng
root
extract
given
elderli
adult
age
year
twice
day
cold
flu
season
period
month
one
month
studi
particip
receiv
influenza
vaccin
first
two
month
signific
differ
durat
incid
observ
compar
placebo
howev
last
two
month
significantli
fewer
subject
ginseng
group
report
acut
respiratori
syndrom
placebo
group
vs
addit
durat
respiratori
symptom
reduc
ginseng
similarli
arrang
trial
healthi
adult
age
year
histori
least
two
cold
previou
year
commenc
month
studi
begin
cold
flu
receiv
two
mg
capsul
daili
standard
american
ginseng
root
extract
placebo
outcom
measur
number
cold
includ
symptom
sever
total
number
symptomat
day
therapeut
effect
report
regard
symptom
sever
fewer
symptom
day
lower
ginseng
group
placebo
group
phase
ii
random
control
trial
dose
schedul
american
ginseng
root
extract
rich
evalu
safeti
toler
efficaci
pediatr
popul
alreadi
suffer
upper
respiratori
tract
infect
result
show
seriou
advers
event
good
toler
ginseng
dose
howev
frequenc
sever
symptom
significantli
differ
among
three
treatment
group
ie
standard
dose
low
dose
promin
constitu
genu
panax
triterpen
saponin
ginsenosid
known
numer
pharmacolog
activ
antivir
effect
compound
chemic
class
show
respons
immunostimul
activ
hand
efficaci
extract
american
ginseng
compar
extract
rich
ginsenosid
system
immun
function
author
studi
investig
lymphocyt
isol
spleen
mesenter
lymph
node
peyer
patch
immun
cell
proport
cytokin
product
rat
could
show
ginseng
extract
modifi
rat
system
immun
respons
affect
immun
manner
distinct
extract
american
direct
antivir
activ
ginseng
constitu
could
attest
polysaccharid
rotaviru
infect
cell
triterpen
saponin
howev
exhibit
rotaviru
activ
moder
vitro
virucid
effect
ginseng
saponin
chikusetsusaponin
iii
herp
simplex
viru
type
detect
fukushima
et
al
compound
exhibit
intracellular
inhibitori
activ
could
margin
affect
viral
protein
ancient
chines
formula
japanes
name
tradit
herbal
medicin
china
japan
compos
ten
speci
medicin
plant
name
astragali
radix
atractylodi
lancea
rhizoma
ginseng
radix
angelica
radix
bupleuri
radix
zizyphi
fructu
aurantii
nobili
pericarpium
glycyrrhiza
radix
cimicifuga
rhizoma
zingiberi
rhizoma
formula
report
variou
yamaya
et
al
recent
investig
effect
cultur
human
airway
epitheli
cell
infect
output
viru
associ
level
viral
rna
product
cytokin
acid
endosom
cell
measur
airway
epitheli
cell
abl
decreas
viru
output
suscept
hrv
infect
decreas
block
entri
viral
rna
cytoplasm
endosom
glycyrrhizin
major
compon
one
herbal
ingredi
ie
glycyrrhiza
glabra
abl
reduc
supernat
viru
titer
maximum
effect
howev
clinic
trial
repres
number
subject
publish
far
p
sidoid
p
reniform
form
origin
popular
drug
umckaloabo
herbal
remedi
south
africa
found
entranc
western
medicin
mainli
aqueou
ethanol
root
extract
p
sidoid
treatment
infect
respiratori
tract
efficaci
umckaloabo
compar
placebo
evalu
adult
suffer
common
cold
lizogub
et
appli
herbal
prepar
well
toler
patient
studi
demonstr
weak
efficaci
umckaloabo
compar
placebo
day
day
howev
p
sidoid
extract
significantli
reduc
sever
symptom
shorten
durat
common
cold
compar
placebo
recent
timmer
et
al
select
random
control
trial
examin
efficaci
p
sidoid
prepar
treatment
variou
acut
respiratori
infect
analyz
efficaci
author
conclud
umckaloabo
may
effect
allevi
symptom
acut
common
cold
adult
may
effect
reliev
symptom
acut
bronchiti
adult
children
sinus
adult
reliabl
data
treatment
acut
respiratori
infect
howev
obtain
identif
metabolit
umckaloabo
reveal
high
number
differ
chemic
class
phenol
cinnam
acid
tannin
flavonoid
coumarin
antibacteri
activ
umckaloabo
differ
pathogen
report
phenol
coumarin
tannin
identifi
contribut
moder
antibacteri
activ
howev
explain
effect
whole
extract
review
addit
p
sidoid
extract
report
significantli
activ
nonspecif
immun
system
induct
tnf
effect
assum
contribut
controversi
discuss
potenti
p
sidoid
extract
treatment
upper
respiratori
tract
infect
one
studi
report
direct
antivir
effect
ie
clear
simplex
viru
acit
aqueou
root
extract
p
pharmacolog
studi
need
elucid
potenti
direct
properti
umckaloaba
constitu
carrageenan
mixtur
differ
polysaccharid
mainli
extract
red
seawe
extens
use
food
cosmet
pharmaceut
industri
thicken
gell
agent
previous
shown
antivir
efficaci
sever
recent
publish
studi
kappa
investig
inhibit
potenti
concentr
sulphat
polysaccharid
abl
fulli
inhibit
cell
death
infect
hela
base
studi
grassauer
et
al
conclud
effect
differ
primari
human
epitheli
cell
hypothes
author
might
creat
hostil
environ
hrv
therebi
block
viral
entri
replic
safe
applic
prove
vitro
efficaci
deserv
consider
candid
clinic
trial
prevent
therapi
common
cold
level
knowledg
impact
six
botan
discuss
differ
heterogen
best
studi
herbal
remedi
associ
common
cold
ie
echinacea
showcas
innat
problem
connect
mixtur
start
late
nineti
till
june
origin
articl
publish
topic
tri
elucid
question
concern
efficaci
molecular
mechan
bioactiv
ingredi
echinacea
although
evid
provid
effect
extract
chemic
class
well
constitu
specif
target
pathway
find
deduc
common
denomin
result
clinic
trial
often
suffer
lack
compar
use
differ
studi
design
outcom
measur
overal
applic
differ
proper
qualiti
analysi
character
prepar
investig
mandatori
follow
recommend
guidelin
report
clinic
trial
herbal
underlin
section
chemic
complex
natur
prepar
might
benefici
term
synergist
addit
overlap
effect
caus
multitud
evolutionari
trim
metabolit
may
attribut
modul
effect
side
exactli
fact
hardli
compat
proper
assign
activ
defin
chemic
entiti
accord
western
medic
practis
contrast
singl
compound
synthet
natur
base
chemistri
botan
complex
also
vari
analyt
profil
term
pharmacolog
profil
investig
sampl
differ
substanti
accordingli
quantit
qualit
comparison
differ
studi
result
botan
far
complex
perform
pure
singl
compound
may
also
explain
littl
emphasi
pharmaceut
industri
put
develop
even
promis
natur
prepar
alreadi
mention
natur
provid
extrem
rich
pool
bioactiv
natur
product
howev
challeng
endeavor
find
exactli
compound
show
activ
focus
target
natur
product
research
hint
folk
medicin
valuabl
start
point
dig
lead
structur
certain
interest
major
activ
principl
higher
plant
discov
result
ethnopharmacolog
direct
pharmacognost
oral
written
indic
benefici
applic
natur
materi
first
need
critic
evalu
select
correct
materi
medicin
prepar
kind
applic
overal
pharmacolog
profil
ration
critic
often
anecdot
efficaci
tradit
medicin
mandatori
attitud
avoid
overinterpret
case
pretend
remedi
report
biolog
efficaci
obvious
suffer
restrict
respiratori
diseas
might
caus
panel
bacteri
viral
infect
thu
approv
remedi
may
affect
microb
show
immun
modul
even
effect
combin
holist
access
innat
charact
ethnopharmacolog
need
track
specif
involv
target
recent
publish
studi
focus
discoveri
binder
natur
use
virtual
screen
ethnopharmacolog
bias
databas
secondari
metabolit
predict
act
inhibitor
depth
phytochem
pharmacolog
investig
mandatori
focu
one
promis
natur
materi
thu
consult
ethnobotan
sourc
materia
medica
written
pedaniu
dioscorid
centuri
ad
treatis
consist
five
book
compris
drug
deriv
miner
anim
major
plant
repres
great
repositori
botan
medic
pharmacolog
lore
scrutin
natur
materi
underli
obtain
virtual
hit
came
across
asafetida
gum
resin
gain
root
varieti
ferula
speci
apiacea
famili
base
descript
given
materia
medica
strong
evid
juic
ie
resin
popular
ancient
silphion
origin
media
syria
correspond
asafetida
book
iii
cap
yield
incis
root
stalk
frequent
mix
sagapenon
ie
resin
f
persica
willd
book
iii
cap
report
effect
context
upper
respiratori
diseas
eg
chronic
harsh
throat
clear
voic
shrink
uvula
suitabl
cough
pleurisi
chest
pain
sagapenon
describ
follow
clear
thick
matter
lung
given
chill
descript
final
help
priorit
virtual
hit
report
constitu
pharmacolog
investig
asafetida
constitu
farnesiferol
b
c
fig
tabl
iii
reveal
distinct
effect
low
micromolar
rang
use
cpe
inhibitori
result
studi
provid
rational
ancient
usag
asafetida
upper
respiratori
tract
infect
hand
tradit
manifest
evid
asafetida
treatment
common
cold
symptom
substanti
help
select
plant
materi
search
capsid
typic
ethnopharmacolog
base
discoveri
activ
extract
follow
bioassay
guid
fraction
isol
constitu
respons
extract
bioactiv
concept
approach
fraction
accompani
simultan
detect
activ
separ
step
result
continu
enrich
final
isol
activ
ingredi
way
larg
number
agent
natur
sourc
alreadi
discov
sempl
et
al
investig
activ
principl
asteracea
plant
pterocaulon
sphacelatum
use
tradit
medicin
aborigin
peopl
australia
favor
treatment
respiratori
infect
especi
cold
mean
antivir
fraction
measur
cpe
assay
author
identifi
flavonoid
ie
chrysosplenol
c
fig
tabl
iii
potent
specif
inhibitor
picornavir
replic
fig
tabl
iii
also
isol
major
constitu
ethanol
extract
p
sphacelatum
show
activ
interestingli
coumarin
exhibit
signific
effect
cpe
assay
recent
perform
virtual
parallel
screen
studi
perform
contrast
isol
coumarin
chrysosplenol
c
alreadi
known
member
repres
potent
specif
inhibitor
picornavir
especi
rhinovir
vanden
bergh
haemer
vlietinck
provid
profound
survey
antivir
agent
higher
plant
demonstr
impact
ethnobotan
knowledg
search
antivir
compound
african
medicin
plant
select
investig
plant
speci
mainli
base
upon
use
treatment
viral
diseas
african
tradit
antivir
activ
differ
plant
speci
belong
famili
investig
thereof
speci
exhibit
promin
antivir
properti
one
test
virus
pronounc
activ
picornavirus
record
within
genu
euphorbia
compound
detect
antivir
constitu
respect
extract
identifi
deriv
especi
quercetin
kaempferol
fig
tabl
iii
show
signific
cytotox
highli
activ
tissu
cultur
human
picornavirus
tissu
cultur
cell
infect
differ
picornavirus
among
also
hrv
cpe
observ
cell
treat
select
natur
materi
base
ethnopharmacolog
profound
rational
lead
structur
discoveri
highli
superior
random
select
howev
rare
appli
marin
organ
fungi
microb
although
organ
esteem
highli
valuabl
sourc
bioactiv
hardli
record
folk
medicin
given
activ
screen
use
robust
reason
effort
time
cost
strategi
get
first
insight
antivir
activ
extract
fraction
compound
synthesi
natur
discoveri
novel
natur
base
hrv
inhibitor
singh
et
al
use
small
peptid
contain
scissil
bond
substrat
vitro
screen
extract
author
isol
novel
benzoisochromanquinon
fig
tabl
iii
extract
fungu
thysanophora
penicilloid
potent
hrv
inhibitori
continu
screen
reveal
pronounc
hrv
inhibitori
activ
extract
chines
herb
polygonum
cuspidatum
fraction
fig
tabl
iii
naphthoquinon
valu
isol
plant
materi
total
synthes
natur
compound
analogu
allow
relationship
particularli
comparison
activ
vs
measur
select
compound
seri
cystein
proteas
hrv
compound
evalu
papain
simpl
fig
tabl
iii
activ
compound
seri
show
valu
distinctli
higher
degre
select
cpe
reduct
assay
appli
identif
raoulic
acid
bicycl
terpen
acid
fig
tabl
iii
isol
raoulia
australi
asteracea
raoulic
acid
exert
antivir
activ
coxsacki
viru
enteroviru
valu
submicromolar
rang
activ
record
influenza
b
cours
systemat
screen
microbi
natur
product
activ
ishitsuka
et
al
identifi
fig
tabl
iii
leav
chines
medicin
plant
agastach
rugosa
lamiacea
natur
compound
high
activ
picornavirus
except
mengoviru
author
synthes
oral
activ
perform
investig
tissu
cultur
mice
determin
compound
mode
action
assum
process
viral
replic
thu
locat
viral
uncoat
initi
viral
rna
activ
flavan
fig
tabl
iii
discov
serendipit
screen
program
use
plaqu
inhibit
base
result
bauer
et
al
synthes
fig
tabl
ii
reveal
activ
number
hrv
serotyp
rang
soon
activ
lead
compound
identifi
utmost
import
scrutin
deriv
activ
obtain
insight
chemic
requir
mandatori
focus
biolog
activ
ii
improv
compound
pharmacolog
profil
term
potenc
select
cytotox
etc
iii
improv
bioavail
nonphenol
aporphin
alkaloid
glaucin
promin
constitu
aerial
part
gaucium
flavum
papaveravea
recent
publish
studi
spasova
et
al
investig
antivir
potenti
glaucin
fig
tabl
iii
glaucin
deriv
hydroxycinnamoyl
amid
besid
potenti
newli
synthes
compound
exert
antivir
activ
replic
best
activ
observ
oxoglaucin
fig
tabl
iii
si
aminomethylglaucin
fig
tabl
iii
si
si
respect
earli
find
activ
natur
deriv
inspir
chemist
pharmacologist
synthesi
pharmacolog
evalu
deriv
thereof
decor
variou
substitut
pattern
sever
report
publish
last
two
decad
review
find
antivir
flavonoid
investig
antivir
activ
wide
varieti
natur
occur
flavonoid
tsuchiya
et
al
found
chrysosplenol
b
c
fig
tabl
iii
contain
chrysosplenium
plant
axillarin
fig
tabl
iii
potent
agent
base
find
flavon
skeleton
decor
methoxi
group
posit
group
reveal
mandatori
seri
antipicornavir
deriv
synthes
de
meyer
et
al
order
establish
relationship
therebi
differ
substitut
pattern
system
methyl
hydroxi
methoxi
halo
nitro
amino
perform
activ
polio
hrv
compar
natur
occur
flavonoid
import
confirm
investig
differ
deriv
lack
result
show
monosubstitut
less
activ
correspond
compound
polysubstitut
within
test
seri
compound
emerg
noncytotox
also
potent
substanc
antivir
test
system
lowest
concentr
compound
protect
cell
cpe
hrv
serotyp
rang
contrast
quercetin
flavon
also
report
mutagen
properti
measur
mgplate
microbi
mechan
studi
perform
shown
interfer
earli
stage
viral
rna
synthesi
induct
resist
contrast
mode
action
chalcon
flavan
report
interact
directli
specif
site
viral
capsid
protein
therebi
prevent
uncoat
consequ
liber
viral
due
potenc
low
toxic
promis
bioavail
dichloroflavan
evalu
protect
efficaci
experiment
two
clinic
trial
howev
drug
candid
fail
either
administ
oral
unfortun
till
clinic
trial
evalu
efficaci
common
cold
perform
common
idea
comput
approach
extract
knowledg
less
larg
set
data
order
make
predict
new
within
lead
discoveri
process
comput
approach
virtual
screen
dock
quantit
relationship
larg
enhanc
impact
comput
chemistri
nowaday
chemoinformat
play
predomin
role
drug
key
goal
use
method
reduc
overal
cost
associ
discoveri
develop
new
drug
identifi
promis
candid
focu
experiment
effort
number
book
review
impact
comput
chemistri
lead
structur
determin
highlight
gener
silico
method
divid
approach
reli
known
activ
compound
base
physicochem
properti
crucial
biolog
affin
activ
predict
extrapol
test
substanc
eg
machin
learn
techniqu
classic
quantit
relationship
qsar
approach
invalu
tool
case
structur
inform
pharmacolog
target
avail
ii
hand
approach
use
experiment
determin
structur
target
molecular
dock
pharmacophor
model
virtual
screen
method
allow
gain
insight
interact
experiment
determin
static
level
howev
consid
flexibl
uniqu
platform
contain
coordin
experiment
solv
protein
structur
crystallographi
nmr
protein
data
bank
pdb
current
compris
structur
biomolecul
addit
sever
web
servic
tool
enabl
use
rich
divers
inform
servic
student
particularli
earli
stage
drug
develop
lead
discoveri
lead
optim
comput
approach
allow
ration
proceed
thu
may
substanti
help
maxim
success
recent
publish
review
impact
approach
antivir
research
thoroughli
describ
underli
silico
techniqu
highlight
benefit
comput
approach
discoveri
antivir
lead
research
capsid
protein
proteas
reveal
promis
target
describ
inhibitor
assum
major
impact
treatment
addit
target
structur
elucid
potent
ligand
known
well
fact
enabl
perform
sensibl
approach
studi
use
silico
approach
discoveri
potenti
agent
focus
mention
target
report
follow
paragraph
compound
act
potenti
binder
classic
qsar
qsar
studi
perform
classic
qsar
relationship
calcul
properti
deriv
chemic
structur
measur
biolog
activ
explor
statist
qsar
techniqu
aim
deriv
correl
turn
activ
predict
base
spatial
arrang
chemic
properti
atom
appli
qsar
techniqu
comfa
compar
molecular
field
analysi
statist
model
deriv
visual
contour
around
molecul
therein
spot
indic
electrostat
properti
spatial
arrang
favor
biolog
studi
diana
et
al
artico
et
al
verma
et
al
qsar
techniqu
help
one
hand
analyz
ration
structur
featur
activ
compound
essenti
interact
hrv
canyon
bind
pocket
hand
search
new
class
capsid
binder
thu
narrow
synthet
challeng
specif
agent
investig
hydrophob
found
one
import
determin
substanc
activ
qsar
combin
simplex
represent
molecular
structur
appli
kuzmin
et
al
base
select
index
inhibitori
concentr
set
biphenyloxi
propyl
isoxazol
basi
qsar
analysi
comput
design
three
new
isoxazol
high
activ
predict
select
synthes
reveal
strong
coincid
experiment
predict
activ
select
index
termin
benzen
substitu
neg
electrostat
potenti
molecul
length
approxim
suggest
mandatori
featur
within
chemic
class
inhibitori
activ
show
high
level
conserv
proteas
bind
site
sequenc
align
secondari
structur
predict
suggest
overal
architectur
mechan
proteas
correl
cellular
serin
proteas
chymotrypsin
ident
among
proteas
differ
famili
howev
modest
provid
space
develop
specif
inhibitor
recent
publish
review
select
inhibitor
picornaviru
replic
de
palma
et
al
summar
current
known
chemic
structur
act
peptid
nonpeptid
inhibitor
viral
reich
et
al
use
hrv
proteas
structur
inform
ration
synthesi
hrv
proteas
inhibitor
class
substitut
benzamid
activ
data
subsequ
crystallograph
studi
point
import
requir
inhibit
similarli
maugeri
et
al
use
approach
perform
dock
studi
base
proteas
crystal
structur
virtual
librari
consist
benzamid
deriv
calcul
propos
substitu
promis
biolog
activ
workflow
guid
design
synthesi
substanc
virtual
assum
act
substrat
analogu
synthesi
compound
biolog
test
confirm
underli
quantit
molecular
model
studi
perform
better
defin
predict
interact
bicycl
deriv
show
irrevers
inhibitor
proteas
studi
molecular
mechan
simul
evalu
chemic
rate
coval
bond
format
free
energi
calcul
combin
crystallograph
studi
appli
explain
differ
activ
irrevers
peptidomimet
inhibitor
data
use
basi
optim
recent
studi
perform
kuo
et
al
compound
subject
high
troughput
screen
search
novel
inhibitor
proteas
picornaviru
coronaviru
five
nonpeptid
identifi
valu
sever
acut
respiratori
one
molecul
found
addit
inhibit
proteas
coxsackieviru
enteroviru
rhinoviru
compound
id
contain
dihydropyrazol
ring
decor
two
phenyl
group
lengthi
use
start
point
select
four
analog
show
valu
rang
test
viral
proteas
mean
comput
model
author
tri
ration
bind
discrep
respons
individu
common
proteas
inhibitor
thu
provid
ration
base
develop
nonpeptid
inhibitor
coronavirus
piciornavirus
research
first
applic
scenario
conduct
use
pharmacophor
model
accord
offici
iupac
definit
wermuth
et
pharmacophor
describ
arrang
steric
electron
featur
necessari
trigger
block
biolog
respons
pharmacophor
repres
chemic
featur
includ
hydrogen
bond
donor
acceptor
aromat
ring
hydrophob
group
well
posit
neg
ionis
moieti
addit
shape
ligand
repres
shape
featur
essenti
describ
van
der
waal
radii
ligand
atom
pharmacophor
concept
proven
success
ration
relationship
also
larg
impact
develop
appropri
effici
virtual
steindl
et
al
elabor
pharmacophor
model
implement
essenti
featur
coval
bind
cystein
activ
site
proteas
thu
silico
approach
focus
defin
new
pharmacophor
featur
repres
target
structur
nucleophil
addit
ligand
crucial
step
proteas
inactiv
gener
hypothes
retriev
known
proteas
inhibitor
virtual
screen
cycl
propos
potenti
unconfirm
ligand
proteas
bind
site
avail
viral
capsid
sever
hrv
elucid
crystal
resolut
hrv
coat
protein
complex
highli
activ
inhibitor
win
use
start
point
gener
pharmacophor
model
steindl
et
al
model
use
virtual
screen
larg
commerci
avail
databas
final
select
virtual
hit
worth
subject
biolog
test
dock
studi
princip
compon
analysi
perform
six
candid
test
abil
inhibit
hrv
serotyp
cpe
inhibit
assay
although
show
certain
antivir
potenti
one
longitudin
piperazin
deriv
inhibit
viru
concentr
test
candid
show
difficulti
interpret
experiment
result
due
rel
high
cytotox
bad
solubl
circumst
ask
cautiou
estim
molecular
properti
compound
select
state
subsequ
perform
studi
best
valid
pharmacophor
model
use
identif
natur
deriv
hrv
coat
protein
virtual
screen
experi
gener
dio
use
describ
base
virtual
predict
ligand
consid
knowledg
tradit
use
sesquiterpen
umbelliferon
gum
resin
ferula
sp
ie
asafetida
final
select
promis
candid
biolog
evalu
antivir
activ
asafetida
isol
constitu
assess
exploratori
determin
inhibit
cpe
induc
hrv
serotyp
result
reveal
select
activ
serotyp
asafetida
virtual
predict
constitu
farnesiferol
b
c
fig
tabl
iii
respect
scrutin
select
two
compound
comparison
test
serotyp
amino
acid
sequenc
align
sinc
amino
acid
residu
involv
ligand
bind
show
match
serotyp
experiment
determin
select
profil
could
explain
differ
bind
pocket
serotyp
align
howev
reflect
potenti
protein
flexibl
bind
might
differ
hrv
serotyp
addit
effect
could
reason
observ
select
recent
perform
virtual
parallel
screen
approach
tri
identifi
potenti
target
human
patholog
relev
constitu
isol
identifi
medicin
plant
ruta
use
screen
platform
piplin
includ
discoveri
conform
identifi
molecul
r
graveolen
subject
parallel
screen
purpos
int
ligand
pharmacophor
model
collect
current
compris
model
cover
uniqu
pharmacolog
target
base
predict
interact
author
focus
three
biolog
target
name
acetylcholinesteras
hrv
coat
protein
cannabinoid
receptor
type
virtual
hit
nonhit
assay
respect
target
critic
evalu
perform
approach
besid
predict
bioactiv
determin
cpe
reveal
virtual
hit
arborinin
fig
tabl
iii
nonpredict
hit
fig
tabl
iii
activ
constitu
could
shown
appli
silico
strategi
capac
catalyz
drug
discoveri
profoundli
diseas
molecular
target
molecular
ligand
well
defin
creat
reliabl
pharmacophor
model
hrv
promin
member
picornavirida
famili
infect
human
frequent
viru
infect
hrv
mainli
lead
upper
respiratori
diseas
common
cold
may
also
caus
sever
lower
respiratori
tract
disord
although
symptomolog
sever
common
cold
rel
mild
cours
diseas
impact
tremend
term
recoup
lost
product
due
sick
leav
last
decad
number
agent
differ
natur
compound
biolog
botan
discov
differ
concept
use
strategi
discoveri
either
start
phenomenolog
effect
eg
empir
knowledg
folk
medicin
molecular
level
eg
icam
capsid
binder
hrv
proteas
inhibitor
outcom
reveal
potent
promis
activ
partli
evalu
manag
common
cold
clinic
trial
mainli
sober
benefit
sinc
hrv
infect
case
potenti
therapi
safe
effect
almost
unrecogniz
level
side
effect
precondit
render
search
high
challeng
endeavor
explain
antivir
agent
approv
prevent
treatment
today
despit
signific
effort
moreov
high
variabl
rhinovirus
suggest
need
one
activ
principl
cover
differ
mode
action
effect
treatment
therefor
high
need
ongo
search
new
synthet
well
natur
compound
molecular
level
increas
knowledg
hrv
life
cycl
gene
protein
sequenc
combin
improv
technolog
field
experiment
comput
method
continu
enabl
insight
spectacular
world
hrv
fundament
research
virtual
screen
approach
qsar
screen
cycl
comput
compound
design
applic
ration
base
gain
expertis
differ
disciplin
adequ
infrastructur
research
encourag
hope
discoveri
clinic
develop
effort
continu
search
agent
may
treat
prevent
annoy
common
cold
judith
maria
rolling
associ
professor
pharmacognosi
institut
pharmaci
univers
innsbruck
studi
pharmaci
univers
innsbruck
austria
receiv
train
microbiolog
pharmaci
univers
hospit
innsbruck
receiv
phd
pharmacognosi
deal
research
crystal
polymorph
univers
innsbruck
postdoctor
time
judith
rolling
extend
studi
field
phytochemistri
ethnopharmacolog
molecular
model
applic
natur
product
scienc
complet
habilit
thesi
entitl
search
bioactiv
natur
product
venia
legendi
professor
pharmacognosi
judith
rolling
project
leader
associ
variou
nation
project
well
execut
guest
editor
current
pharmaceut
design
award
phoenix
scienc
award
receiv
sever
addit
award
research
focus
interdisciplinari
field
integr
comput
techniqu
classic
pharmacognost
research
strategi
discoveri
bioactiv
natur
product
treat
neurodegen
diseas
viral
infect
inflamm
michaela
schmidtk
associ
professor
institut
virolog
antivir
therapi
univers
clinic
center
jena
germani
studi
biolog
receiv
diploma
microbiolog
univers
chisinau
moldowa
obtain
phd
degre
faculti
biolog
univers
jena
germani
deal
antivir
investig
select
picornavirus
vitro
postdoctor
research
fellow
institut
immunolog
univers
marburg
studi
cell
interact
cytokin
induct
thereaft
postdoctor
fellow
institut
virolog
antivir
therapi
univers
clinic
center
jena
germani
receiv
venia
legendi
virolog
habilit
thesi
deal
develop
select
antivir
compound
enterovirus
research
interest
focu
develop
novel
inhibitor
respiratori
virus
particularli
enterovirus
influenza
virus
